Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

Josep Darbà,1 Lisette Kaskens,2 Francesc Sorio Vilela,3 Mickael Lothgren4 1Department of Economics, Universitat de Barcelona, 2BCN Health Economics and Outcomes Research SL, 3Amgen SA, Barcelona, Spain; 4Amgen (Europe) GmbH, Zug, Switzerland Background: The objective of this study was t...

Full description

Bibliographic Details
Main Authors: Darbà J, Kaskens L, Sorio Vilela F, Lothgren M
Format: Article
Language:English
Published: Dove Medical Press 2015-02-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/cost-utility-of-denosumab-for-the-treatment-of-postmenopausal-osteopor-peer-reviewed-article-CEOR

Internet

http://www.dovepress.com/cost-utility-of-denosumab-for-the-treatment-of-postmenopausal-osteopor-peer-reviewed-article-CEOR

Similar Items